United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Has $27.70 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 16.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 374,119 shares of the medical research company’s stock after selling 76,114 shares during the quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund owned 0.06% of Edwards Lifesciences worth $27,696,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Banco BTG Pactual S.A. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $508,000. Baxter Bros Inc. boosted its stake in shares of Edwards Lifesciences by 3.0% during the fourth quarter. Baxter Bros Inc. now owns 87,824 shares of the medical research company’s stock valued at $6,502,000 after purchasing an additional 2,556 shares in the last quarter. TIAA Trust National Association increased its stake in shares of Edwards Lifesciences by 6.4% in the fourth quarter. TIAA Trust National Association now owns 10,943 shares of the medical research company’s stock valued at $810,000 after buying an additional 656 shares during the period. Prudential Financial Inc. boosted its position in Edwards Lifesciences by 16.2% during the 4th quarter. Prudential Financial Inc. now owns 432,460 shares of the medical research company’s stock worth $32,015,000 after buying an additional 60,171 shares during the period. Finally, Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences in the 4th quarter valued at approximately $26,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares of the company’s stock, valued at $4,106,859.33. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 400 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the sale, the vice president now directly owns 22,588 shares of the company’s stock, valued at $1,569,414.24. The trade was a 1.74 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,303 shares of company stock valued at $3,715,776. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Stock Down 0.1 %

Edwards Lifesciences stock opened at $71.29 on Wednesday. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm’s 50-day simple moving average is $71.43 and its 200 day simple moving average is $70.45. The stock has a market cap of $41.91 billion, a PE ratio of 10.23, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on EW shares. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Barclays increased their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Canaccord Genuity Group upped their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday, February 13th. Wolfe Research lowered shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group upped their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.